Welcome to our dedicated page for HYPERFINE news (Ticker: HYPR), a resource for investors and traders seeking the latest updates and insights on HYPERFINE stock.
Hyperfine, Inc. (Nasdaq: HYPR) is a health technology and medical device company that focuses its news flow on developments around the Swoop® Portable MR Imaging® System, an FDA-cleared, portable, ultra-low-field brain MRI platform. Company press releases emphasize regulatory milestones, clinical studies, financial results, and global health initiatives tied to this AI-powered portable MRI technology.
Investors and clinicians following HYPR news can expect regular updates on clinical research and indication expansion efforts. Recent announcements include the enrollment of the first patient in the Contrast PMR study, a prospective, multi-center trial designed to evaluate contrast-enhanced ultra-low-field portable MRI to support a future FDA submission for expanded intended use of the Swoop® system with gadolinium-based contrast agents. Other clinical news has highlighted the PRISM PMR study, which evaluates the Swoop® system’s use in neurosurgical operating room settings, and a peer-reviewed publication describing the economic impact of integrating the Swoop® system into acute hospital care.
Hyperfine’s news feed also features regulatory and market access updates, such as regulatory approval of the Swoop® system in India by the Central Drugs Standard Control Organization (CDSCO), as well as CE Mark and UKCA Mark approvals for its Optive AI™ software. Financial and corporate news includes quarterly and preliminary unaudited financial results, capital raises through public offerings, participation in healthcare conferences, and business updates related to the commercial rollout of the next generation Swoop® system and Optive AI™ software.
For those tracking HYPR, the news stream provides insight into the company’s progress in hospital and neurology office adoption, its international expansion, and its collaborations on global brain health projects such as the UNITY initiative. Bookmarking this page allows readers to monitor how Hyperfine’s clinical, regulatory, and financial developments evolve over time.
Hyperfine (NASDAQ: HYPR) has received FDA clearance for its Optive AI™ software, a significant upgrade for its Swoop® system - the world's first FDA-cleared AI-powered portable MRI system for brain imaging. The tenth-generation software release delivers substantial improvements in image quality through enhanced AI algorithms that optimize noise cancellation, image acquisition, reconstruction, and post-processing.
Early clinical users reported image quality approaching that of conventional 1.5 tesla MRI scanners. The company plans to roll out the software to accounts in Q3 2025. This release represents one of two major technology milestones for 2025, supporting Hyperfine's growth strategy for expansion into new hospital sites and entry into the neurology office market.
Hyperfine (NASDAQ: HYPR), known for developing the Swoop® system - the first FDA-cleared AI-powered portable magnetic resonance brain imaging system, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's management will deliver a presentation on Thursday, June 5th at 4:20pm ET and will be available for in-person meetings on Wednesday, June 4th. Interested parties can schedule one-on-one meetings through their Jefferies representative.
Hyperfine (Nasdaq: HYPR), creator of the pioneering Swoop® system - the first FDA-cleared portable magnetic resonance brain imaging system - has scheduled its Q1 2025 financial results announcement for May 13, 2025.
Key Details:
- Event Date: Tuesday, May 13, 2025
- Conference Call Time: 1:30 PM Pacific / 4:30 PM Eastern
- Access: Live audio webcast available through Hyperfine's investor relations website
- Registration: Participants should register at least 15 minutes before the call
The webcast recording will be archived and accessible through the company's investor portal at https://investors.hyperfine.io/
Hyperfine (NASDAQ: HYPR) has initiated the NEURO PMR (Neurological Evaluation in the Office with Portable MRI) study, enrolling initial patients to evaluate their AI-powered portable MRI system in neurology offices. This multi-center study compares their Swoop® system, first FDA-cleared in 2021, with conventional high-field MRI systems.
The study, conducted at the DENT Neurologic Institute and Texas Neurology, targets 100 patients and aims to conclude by year-end. It will assess pathology findings, clinical utility, and patient experience. The portable system offers significant advantages, requiring no costly siting, helium, or specialized MRI technologists.
Notably, starting November 2024, IAC Accredited medical offices using portable MRI systems will qualify for Centers for Medicare and Medicaid Services (CMS) reimbursement, potentially expanding accessibility in underserved, rural, and community centers.
Hyperfine (HYPR) reported Q4 2024 financial results, with revenues of $2.32 million, down from $2.69 million in Q4 2023. The company sold 9 Swoop® systems in Q4 2024 versus 7 in Q4 2023.
Full year 2024 revenues increased 17% to $12.89 million, with 48 Swoop® systems sold compared to 37 in 2023. Gross margin improved to 46% from 43%. Net loss for 2024 was $40.72 million ($0.56 per share), improved from $44.24 million ($0.62 per share) in 2023.
The company strengthened its financial position through a $6.0 million registered direct offering, extending cash runway through 2026. For 2025, management projects revenue growth of 20-30% and reduced cash burn of $25-27 million, a 32% decline from 2024.
Hyperfine (Nasdaq: HYPR) has announced a strategic collaboration with NVIDIA to enhance its AI-powered portable MRI technology. The partnership focuses on advancing the Swoop® system, the first FDA-cleared AI-powered portable magnetic resonance brain imaging system.
The collaboration aims to leverage NVIDIA's AI expertise and accelerated computing to make brain MRI faster, smarter, and more affordable globally. Using NVIDIA's advanced suite of training and inference tools, including NVIDIA DALI and MONAI, the partnership will work on improving image quality, reducing scan times, and enabling faster diagnoses.
This initiative addresses a critical healthcare gap, as 90% of the global population lacks access to timely MRI diagnostics due to conventional MRI systems' high costs and infrastructure requirements. The Swoop® system is designed for point-of-care use in professional healthcare settings by trained clinicians, targeting the over three billion people worldwide affected by brain diseases.
Hyperfine (Nasdaq: HYPR), creator of the first FDA-cleared portable magnetic resonance brain imaging system—the Swoop® system, has scheduled its fourth quarter and full year 2024 financial results announcement for March 17, 2025. The company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day. Investors can access both the live audio webcast and recording through the company's investor relations website.